Table 4.

HBV Markers Among Subjects With Possible HBV Reactivation^a

Markers	CUI-213 (Female, Aged 51)b Week						CUI-238 (Female, Aged 47) Week						CUI-321 (Male, Aged 48) Week
	0	4	12	24	36	48	0	4	12	24	36	48	0	4	12	24	36	48
HBsAg	-		-				-				-		-					-
Anti-HBs	-		-				+				+		+				+	++++
Anti-HBc	+						++				++		+				+
Anti-HBe	+						+						-
HBV DNA	-	-	+				-		-		+		-		-		-	+
AST U/L	19	12	10	23	15	15	33	24	26	31	28	24	14	12	14	16	19	21
ALT U/L	15	13	17	16	14	30	17	14	35	33	10	26	8	11	11	23	17	21
HIV-1 RNAc	UD		UD	UD	UD	UD	UD		UD	UD	496	1098	UD		UD	UD	UD	UD
CD4 countd	566			728		680	449			495		484	143			154		192
NRTIs	TDF 3TC	None	None	TDF 3TC	TDF 3TC	TDF 3TC	TDF 3TC	None	None	None	None	None	TDF 3TC	None	None	None	None	None

Abbreviations: ALT, alanine transaminases; anti-HBc, total hepatitis B core antibody; anti-HBe, hepatitis B e antibody; anti-HBs, hepatitis B surface antibody; AST, aspartate transaminase; 3TC, lamivudine; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NRTIs, nucleos(t)ide reverse transcriptase inhibitors; TDF, tenofovir disoproxil fumarate; UD, undetectable (<60 copies/mL).

^aAfter study entry, study visits were planned at weeks 4, 12, 24, 36, and 48. Given the retrospective nature of the analysis, stored samples for HBV testing were not available from all study visits; missing time points are blank.

^bPatient returned to standard of care triple ART at week 19 due to an adverse event and was recalled at weeks 24, 36, and 48 for poststudy assessment.

^cPlasma HIV-1 RNA load in copies/mL.

^dCD4 count in cells/mm³.